Form 4: 4D Molecular Therapeutics Chief Legal Officer Exercises and Sells Stock Options
SEC Form 4 Filing
Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- On April 16, 2024, Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options to acquire 500 shares at $6.49 and 1,250 shares at $8.04.
- He then sold 1,750 shares of common stock at $25.74.
- These transactions were executed under a 10b5-1 trading plan adopted on October 10, 2023.
- Following these transactions, Bizily directly owns 1,737 shares of common stock and holds options to purchase 53,379 more.
Sentiment
Score: 5
Explanation: This is a routine disclosure of insider transactions. The sentiment is neutral as it reflects standard executive compensation and trading activity.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- Shareholders may be interested in insider trading activity as it can provide insights into management's view of the company's prospects.
Key Dates
| Date | Description |
|---|---|
| October 10, 2023 | Date the Reporting Person adopted the 10b5-1 trading plan |
| June 16, 2022 | Vesting Commencement Date for some stock options |
| September 1, 2022 | Vesting Commencement Date for some stock options |
| April 16, 2024 | Date of the reported transactions (exercise and sale of stock options) |
| April 18, 2024 | Date of the report |
| 06/17/2032 | Expiration date of some stock options |
| 08/31/2032 | Expiration date of some stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.